Our Newsletter “Deal Capsule Life Sciences” offers regular insights into selected transactions, developments in the M&A market and the issues shaping the transaction landscape of the global life sciences sector – from risk-conscious acquisition strategies to innovation priorities in areas such as oncology and immunology. In addition, our experts provide further insights into market trends and shed light on a specific topic relating to the global transactions and investment market.
Register now:
Archive Issues
Here you will find the past issues of the newsletter, covering selected deals, developments in the M&A market, and the key issues shaping the sector’s transaction market.
- Current Issue
- Archive
An overview of the topics in the current issue (August 2026)
- Deal value and volume: H1 2026 saw transaction activity accelerate, with larger deal sizes reflecting demand for growth assets and the need to address impending exclusivity losses. Available capital and continued appetite for innovation-supported dealmaking activity across the sector.
- Strategic priority: Private equity investors remained active, particularly in corporate carve-out situations, consolidation opportunities and portfolio repositioning initiatives aimed at creating value.
- M&A focus: Deal activity gravitated toward late-stage and near-commercial assets offering revenue visibility and commercial scalability. Acquirers also targeted platform technologies and AI-enabled capabilities to strengthen R&D processes, accelerate product development, and support commercial execution.
- Ruling therapy areas: Cardio-metabolic diseases, immunology, oncology, and neurology attracted substantial investor interest, with activity centered on clinically validated assets and pipeline expansion opportunities.
Your contact
Christian Klingbeil
Partner, Deals & Performance, Valuation, Head of Life Sciences & Chemicals
KPMG AG Wirtschaftsprüfungsgesellschaft